Trial Profile

A retrospective study of utilization of lenalidomide and dexamethasone (KRd) and dexamethasone alone (Kd) in routine clinical practice in APAC, including treatment patterns, patient profile, reasons for discontinuation, clinical outcomes, and frequency of adverse events

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Cyclophosphamides; Daratumumab; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

19 Jan 2023 New trial record
13 Dec 2022 Interim results (at data cutoff: 1 April 2022; n= 273) presented at the 64th American Society of Hematology Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com